IDEXX Laboratories Inc. has announced the launch of the Catalyst® Cortisol Test, designed to measure real-time quantitative cortisol concentrations in dogs. This test aids in diagnosing Addison's disease and managing Cushing's syndrome, marking the third expansion of the Catalyst platform within a year. The Catalyst Cortisol Test is integrated with IDEXX Vetlab® Station and VetConnect® PLUS, providing real-time interpretive guidance during patient visits. The new test offers a load-and-go workflow, allowing it to run alone or with additional chemistry tests from a single sample. This feature is intended to improve efficiency by reducing sample preparation time and ensuring consistent results. The Catalyst Cortisol Test will be available in the U.S. and Canada by the end of July 2025, with an international rollout planned for the third quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.